ARS Pharmaceuticals, Inc. (SPRY) Profit Margins
Over the twelve months to 2026-06-30, ARS Pharmaceuticals, Inc. (SPRY) had operating margin -185.0%, net margin -184.2%, free cash flow margin -168.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SPRYARS Pharmaceuticals, Inc.Follow SPRY — free
—
Price chart with a free account
- Market cap
- 400.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Gross margin | — | 100.0% | — | — | — | |
| Operating margin | -2698.8% | -225066.7% | -3.5% | -212.9% | -185.0% | |
| Net margin | -2635.4% | -181216.7% | 9.0% | -203.3% | -184.2% | |
| FCF margin | -3060.6% | -198136.7% | 14.6% | -203.1% | -168.1% |
USD millions · SEC XBRL
ARS Pharmaceuticals, Inc. — questions
- What is ARS Pharmaceuticals, Inc.'s operating margin?
- -185.0% over the twelve months to 2026-06-30.
- What is ARS Pharmaceuticals, Inc.'s net profit margin?
- -184.2% over the twelve months to 2026-06-30.
Every figure on this page comes from ARS Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.